Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Growth Metrics

Guided Therapeutics (GTHP) Long-Term Deferred Tax (2016 - 2024)

Guided Therapeutics' Long-Term Deferred Tax history spans 5 years, with the latest figure at $17.6 million for Q4 2024.

On a quarterly basis, Long-Term Deferred Tax changed N/A to $17.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $17.6 million, a N/A change, with the full-year FY2024 number at $17.6 million, changed N/A from a year prior.
Long-Term Deferred Tax hit $17.6 million in Q4 2024 for Guided Therapeutics, down from $21.0 million in the prior quarter.
Over the last five years, Long-Term Deferred Tax for GTHP hit a ceiling of $17.6 million in Q4 2024 and a floor of $17.6 million in Q4 2024.